Historical record - last NADAC effective date: 10/23/2019
Product Information
RIVASTIGMINE 1.5 MG CAPSULE is a generic product labeled by Nivagen Pharmaceuticals Inc., priced at $0.3616 per EA under NDC 75834013305. Its NADAC has been published 95 times since Feb 14, 2018.
FDA first approved this application on Feb 13, 2017. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the RIVASTIGMINE TARTRATE market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
1.5 mg/1
Manufacturer
Nivagen Pharmaceuticals Inc.NDC
75834013305
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
10/23/2019
Active Ingredients
RIVASTIGMINE TARTRATEApproval Type
Generic (ANDA)
FDA Application
ANDA203844FDA Approved
2/13/2017
TE Code
AB
On Market Since
9/4/2017
Pharmacological Classes
Price Statistics
The NADAC for RIVASTIGMINE 1.5 MG CAPSULE has been published 95 times since Feb 14, 2018, and over the history we have for it it has declined 45.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.3616 per EA |
|---|---|
| All-time high | $0.9925 (Apr 11, 2018) |
| All-time low | $0.2616 (Mar 20, 2019) |
| Median price | $0.3876 |
| Average price | $0.4621 |
| Largest weekly change | +44.1% (Apr 17, 2019) |
| Weeks tracked | 95 |
| Tracking since | Feb 14, 2018 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
N/A
5Y
N/A
All
-45.9%
Last surveyed Dec 4, 2019 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 56% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of RIVASTIGMINE 1.5 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for RIVASTIGMINE 1.5 MG CAPSULE, manufactured by Nivagen Pharmaceuticals Inc., is $0.3616 per EA (NDC 75834013305), effective Dec 4, 2019.
How has the price of RIVASTIGMINE 1.5 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for RIVASTIGMINE 1.5 MG CAPSULE has declined 45.9%. It has been tracked across 95 weekly CMS publications since Feb 14, 2018.
What are the highest and lowest recorded NADAC prices for RIVASTIGMINE 1.5 MG CAPSULE?
Since Feb 14, 2018, the NADAC for RIVASTIGMINE 1.5 MG CAPSULE has ranged from a low of $0.2616 (Mar 20, 2019) to a high of $0.9925 (Apr 11, 2018), with a median of $0.3876 per EA.
Are there cheaper alternatives to RIVASTIGMINE 1.5 MG CAPSULE?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, RIVASTIGMINE 1.5 MG CAPSULE, is $0.1590 per EA — about 56% below RIVASTIGMINE 1.5 MG CAPSULE.
Who manufactures RIVASTIGMINE 1.5 MG CAPSULE?
RIVASTIGMINE 1.5 MG CAPSULE (NDC 75834013305) is labeled by Nivagen Pharmaceuticals Inc., and CMS classifies it as a generic product.